PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC
Epistemonikos ID: d388d2e05b7345072d807dab5f6676b2fdc32b64
First added on: Oct 01, 2024